Kashyap Patel, MD, discusses how biosimilars impact cost in the Medicare Part B context.
Biosimilars are really a very good solution to the ever-rising Part B drug price, and they have directed the reference biologic manufacturers to come and become competitive. That’s how we’re seeing the subcutaneous molecule for rituximab, which actually is going to be standing up firm against the biosimilar in the market.
Any competition in the market helps improve the cost, helps improve the patient’s convenience, and helps the physicians as well. So at the end of the day, it’s all about treating patients right, saving dollar volume for the Part B drug space, and doing good for all.